Investment Summary: 10x Genomics (TXG) Initiation Coverage (FY2023-FY2025)
- Transition to Recurring Revenue Model: Over the last three years, 10x Genomics has shifted from a high-growth instrument seller to a consumables-driven, recurring-revenue model. Consumables now dominate the revenue mix, with spatial biology platforms (Xenium, Visium) driving robust growth.
- Financial Performance: Revenue grew from $618.7M in FY2023 to $642.8M in FY2025 (+5% YoY in FY2025), despite macro headwinds and declining instrument sales. Net losses narrowed significantly, from -$255.1M in FY2023 to -$43.5M in FY2025, aided by cost discipline and non-recurring IP settlements.
- Product Innovation and Segment Dynamics: Major launches (Flex Apex, Atera, GEM-X, Visium HD, Xenium 5K) fueled double-digit reaction volume growth, especially in spatial consumables. Single cell consumables faced pricing pressure but offset by higher volumes. Instrument sales declined sharply, reflecting market saturation and centralization trends.
- Strategic Actions: Acquisitions (Scale Biosciences, Proteintech Genomics) and favorable patent litigation settlements (Vizgen, Bruker) strengthened technology portfolio and IP position. Operating expenses were reduced through restructuring and workforce cuts.
- Macro and Competitive Headwinds: Academic/government funding uncertainty, CapEx constraints, and competitive pressures persisted. Management withdrew annual guidance in FY2025 due to funding volatility.
- Cash Position and Resilience: Ended FY2025 with $523.4M in cash and securities, supporting ongoing investment and potential future acquisitions.
Business Overview
10x Genomics develops instruments, consumables, and software for single cell and spatial biology research. Its platforms (Chromium, Xenium, Visium, Atera) serve academic, biopharma, and translational customers globally. Revenue is primarily from consumables, with instruments and services as secondary drivers.
Financial Snapshot: Key Material Information (Fiscal Years)
| Fiscal Year | Revenue ($M) | YoY Growth (%) | Gross Margin (%) | Net Loss ($M) | Operating Expenses ($M) | Cash & Equiv. ($M) | Cumulative Instruments Sold | Consumable Reactions Sold | License/Royalty Revenue ($M) | Inventory Write-downs ($M) |
|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 | 642.8 | +5 | 69 | -43.5 | 504.9 | 523.4 | 8,046 | 424,000 | 46.1 | 26.5 |
| FY2024 | 610.8 | -1 | 68 | -182.6 | 609.0 | 393.4 | 7,039 | 357,100 | 0.3 | 11.3 |
| FY2023 | 618.7 | +20 | 66 | -255.1 | 674.6 | 388.7 | 5,966 | 347,000 | - | - |
Segment/Product Trends (FY2025)
| Product/Segment | Revenue ($M) | YoY Change | Notes |
|---|---|---|---|
| Instruments | 56.8 | -39% | Lower ASPs, fewer units sold, price reductions |
| Consumables | 507.2 | +3% | Driven by spatial consumables, offsetting single cell decline |
| Services | 32.7 | +35% | More service plans as installed base matures |
| License & Royalty | 46.1 | n.m. | One-time settlements (Vizgen, Bruker) |
Quarterly Financial Snapshot (Q3 2025-Q2 2026)
| Quarter | Revenue ($M) | YoY Growth | Gross Margin (%) | Cash ($M) | Single Cell Cons. Growth | Spatial Cons. Growth | Notable Events |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 151.0 | +3%* | 74* | 552 | +3% | +16% | Atera demand strong, orders > supply |
| Q1 2026 | 150.8 | +9%* | 70 | 540 | +6% | +31% | Atera launch, Flex Apex momentum |
| Q4 2025 | 166.0 | +1% | 68 | 523 | +3% | +14% | Modest budget flush, Flex Apex launch |
| Q3 2025 | 149.0 | -2% | 67 | 482 | -4% | +19% | Macro headwinds, strong Xenium |
*Excludes nonrecurring settlement/license revenue.
Bullish and Bearish Points
| Bullish Points | Bearish Points |
|---|---|
| Strong improvement in net loss and operating leverage in FY2025 | Instrument revenue down sharply (-39% YoY), indicating possible market saturation or pricing pressure |
| Recurring consumables revenue is growing and now dominates the revenue mix | Single cell consumables revenue declined YoY |
| Large cash position ($523.4M FY2025, $552M Q2 2026) supports continued investment and resilience | Inventory write-downs ($26.5M in FY2025) signal challenges in demand forecasting/product transitions |
| Patent litigation settlements provide non-recurring revenue and IP validation | Heavy reliance on academic/government funding, which remains uncertain |
| Strategic acquisition of Scale Bio expands technology portfolio | Ongoing legal risks and competitive threats from established and emerging players |
| Cost discipline: R&D and SG&A both reduced YoY | Non-recurring license/royalty revenue in FY2025 not expected to repeat |
| Atera launch expands TAM and cements leadership in spatial biology | Macro headwinds: academic/government funding remains constrained |
| Flex Apex drives double-digit reaction growth and broadens access | Pricing pressure from lower-cost assays impacts single cell revenue growth |
| AI-driven research and translational/clinical applications are structural tailwinds | CapEx environment remains tight; instrument sales under pressure |
Positive and Negative Catalysts
| Positive Catalysts | Negative Catalysts |
|---|---|
| Successful integration and commercialization of Scale Bio technology | Further declines in instrument sales or consumables revenue |
| Expansion into clinical/diagnostic markets | Reduction or delays in academic/government research funding |
| New product launches in spatial/single cell platforms (Atera, Flex Apex, Visium HD, Xenium 5K) | Adverse outcomes in ongoing patent litigation (e.g., Parse, Curio, Illumina) |
| Additional IP licensing settlements or monetization | Increased competition from new entrants or established players |
| Growth in international markets, especially China and EMEA | Supply chain disruptions, tariffs, or regulatory changes |
| Ramp of Atera shipments in Q4 2026 and into 2027 | Transition to Atera causing near-term delays in spatial consumables/instrument purchases |
| Acceleration of AI-driven large-scale projects (e.g., CZI, Arc Institute, Bioptimus) | Prolonged CapEx constraints, especially in US/Europe |
| Improved macro/funding environment | Pricing pressure persists longer than expected, limiting revenue leverage |
Top Questions to Ask Before Investing
- Sustainability of Consumables Growth: Can consumables revenue growth offset declining instrument sales over the medium term?
- Recurring vs. Non-Recurring Revenue: How much of recent revenue growth is sustainable, given the one-time nature of license and royalty settlements?
- Competitive Position: How defensible is 10x’s IP portfolio against emerging competitors and ongoing litigation?
- Clinical Market Entry: What is the timeline and likelihood of success for entering the clinical/diagnostic markets, and what regulatory hurdles remain?
- Funding Environment Exposure: How sensitive is the business to changes in academic/government funding, especially NIH appropriations?
- Product Transition Risks: How will management mitigate further inventory write-downs and demand forecasting errors during product transitions?
- Integration of Scale Bio: What are the expected synergies and milestones for the Scale Bio acquisition, and how will it impact the core business?
- International Risk: How exposed is the company to geopolitical risks, especially in China and Taiwan, and what mitigation strategies are in place?
- Gross Margin Sustainability: Can gross margins be maintained or improved absent further IP settlements?
- Capital Allocation: With a large cash balance, what is the capital allocation strategy, further M&A, R&D, or return to shareholders?
- Atera Ramp and Execution: How quickly can 10x scale Atera manufacturing and installations to meet demand? What are the risks of delays or field issues?
- Pricing Dynamics: When will pricing headwinds from Flex Apex and other lower-cost assays stabilize, and what is the long-term impact on single cell revenue growth?
